Full text

Turn on search term navigation

© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background

Smoking and vaping are linked to lung inflammation and lowered immune response.

Objective

Examine the prevalence of coronavirus disease 2019 (COVID-19) cases, testing, symptoms, and vaccine uptake, and associations with tobacco product use.

Methods

Data came from the 2021 National Health Interview Survey. The 2021 Sample Adult component included 29,482 participants with a response rate of 50.9%. We investigated COVID-19-related outcomes by tobacco product use status and reported national estimates. Multivariable regression models were performed accounting for demographics (e.g., age, sex, poverty level), serious psychological distress, disability, and chronic health conditions.

Results

In our regression analyses, odds of self-reported COVID-19 infection were significantly lower for combustible tobacco product users (vs. nonusers; adjusted odds ratio [AOR = 0.73; 95% confidence interval [CI] = 0.62–0.85]). Combustible tobacco users also were less likely to report ever testing for COVID-19 (AOR = 0.88; 95% CI = 0.79–0.98), ever testing positive for COVID-19 (AOR = 0.66; 95% CI = 0.56–0.77), and ever receiving COVID-19 vaccine (AOR = 0.58; 95% CI = 0.51–0.66) compared with their nonuser peers. Compared to nonusers, users of any type of tobacco who contracted COVID-19 had higher odds of losing smell (AOR = 1.36; 95%CI = 1.04–1.77), which was more pronounced among exclusive e-cigarette users. The odds of receiving vaccine were lower for all current exclusive tobacco product users compared to nonusers (AORs = 0.40 to 0.70).

Conclusions

Continued monitoring of tobacco product use and its association with respiratory diseases such as COVID-19 is crucial to inform public health policies and programs. In addition, efforts to promote vaccination, especially among tobacco product users, are warranted.

Details

Title
COVID-19 and tobacco products use among US adults, 2021 National Health Interview Survey
Author
Mohammad Ebrahimi Kalan 1   VIAFID ORCID Logo  ; Rime Jebai 2 ; Li, Wei 3 ; Gautam, Prem 4 ; Seyedeh Yasaman Alemohammad 2 ; Mortazavizadeh, Zeinab 5 ; D. Ward Kenneth 6 ; Chakraborty, Aditya 1   VIAFID ORCID Logo  ; Ghader Dargahi Abbasabad 7 ; Behaleh, Raed 8 ; Bursac, Zoran 9 ; Ziyad Ben Taleb 10 

 Eastern Virginia Medical School, Norfolk, Virginia, USA 
 Department of Epidemiology, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA 
 Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, Connecticut, USA 
 Texas State Board of Pharmacy, Austin, Texas, USA 
 Department of Psychology, The University of Alabama at Birmingham, Birmingham, Alabama, USA 
 School of Public Health, University of Memphis, Memphis, Tennessee, USA 
 University of New Brunswick, Fredericton, California, USA 
 School of Health Sciences, Baldwin Wallace University, Berea, Ohio, USA 
 Department of Biostatistics, Robert Stempel College of Public Health, Florida International University, Miami, Florida, USA 
10  Department of Kinesiology, College of Nursing and Health Innovation, University of Texas at Arlington, Arlington, Texas, USA 
Section
ORIGINAL RESEARCH
Publication year
2023
Publication date
Sep 2023
Publisher
John Wiley & Sons, Inc.
e-ISSN
23988835
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2869161964
Copyright
© 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.